# Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

> **NCT02675439** · PHASE1 · TERMINATED · sponsor: **Chinook Therapeutics, Inc. (formerly Aduro)** · enrollment: 47 (actual)

## Conditions studied

- Advanced/Metastatic Solid Tumors or Lymphomas

## Interventions

- **DRUG:** ADU-S100
- **BIOLOGICAL:** ipilimumab

## Key facts

- **NCT ID:** NCT02675439
- **Lead sponsor:** Chinook Therapeutics, Inc. (formerly Aduro)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-28
- **Primary completion:** 2019-12-11
- **Final completion:** 2020-08-06
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** No substantial anti-tumor activity was observed.
- **Last updated:** 2021-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02675439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02675439, "Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02675439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*